Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers

#2904

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.

Aim(s): Describe a retrospective cohort of patients with advanced digestive G3 NETs and depict their prognosis and treatment.

Materials and methods: Patients with advanced digestive G3 NET were included from 4 expert centers. Central pathological review was performed. Response rates (RR) to the two first treatment lines (primary endpoint) was analyzed depending on the type of treatment: neuroendocrine carcinoma (NEC)-like, alkylating agent (temozolomide or streptozotocin) (ALK), or somatostatin analogs (SSAs). Factors associated with RR and overall survival (OS) were assessed using logistic or Cox regression models, respectively.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,

Keywords: grade 3, prognosis, treatment, alkylating agents,